managing-hypertensive-emergencies

name	managing-hypertensive-emergencies
description	Guides urgent blood pressure management with target reduction rates and IV medication protocols. Use when managing hypertensive crises, selecting IV antihypertensives, or monitoring acute BP reduction.
tags	["management","cardiology"]
metadata	{"author":"casemark","practice_areas":["Cardiology","Interventional Cardiology","Electrophysiology"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Hypertensive Emergencies

Guides urgent blood pressure management with target reduction rates and IV medication protocols.

Why This Skill Exists

Hypertensive emergencies — defined as severely elevated BP (often > 180/120 mmHg) with acute end-organ damage — carry mortality rates of 1–2% per hour if untreated. The distinction between hypertensive emergency (end-organ damage present) and hypertensive urgency (elevated BP without acute damage) is critical, as management strategies differ fundamentally: emergencies require IV therapy with controlled rate of BP reduction, while urgencies can be managed with oral agents.

The 2017 ACC/AHA Hypertension Guideline and critical care consensus documents define target reduction rates specific to each end-organ presentation. Overly rapid BP reduction risks watershed infarction, especially in patients with chronic hypertension whose autoregulatory curve is right-shifted.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the current blood pressure (both arms if aortic dissection suspected)? (default: "BP not documented")
2. Is there evidence of acute end-organ damage — which organ system? (default: "End-organ status not assessed")
3. What is the timeline of BP elevation — acute onset or chronically elevated? (default: "Timeline unknown")
4. What is the neurologic examination status? (default: "Neuro exam not documented")
5. What is the current renal function (Cr, BUN, urinalysis with sediment)? (default: "Renal function not provided")
6. Is there chest pain, dyspnea, or signs of aortic dissection? (default: "Cardiac symptoms not assessed")
7. What antihypertensive medications is the patient currently prescribed (compliance)? (default: "Medication adherence not documented")
8. Are there any known secondary causes of hypertension (pheochromocytoma, renal artery stenosis, primary aldosteronism)? (default: "No secondary cause suspected")

Documents to Request

• Current vital signs with BP in both arms
• Fundoscopic examination findings
• 12-lead ECG
• Chest X-ray
• BMP (Cr, BUN, electrolytes)
• Urinalysis with microscopy (RBC casts, proteinuria)
• Troponin (if chest pain or ECG changes)
• CBC with peripheral smear (if TMA suspected)
• CT head (if neurologic symptoms)
• CT angiogram (if dissection suspected)
• Pregnancy test (if applicable — eclampsia workup)
• Current medication list and compliance assessment

---

Step 1: Classify Emergency vs. Urgency

Hypertensive Emergency (requires IV therapy, ICU monitoring):

End-Organ Target	Presentation	Key Diagnostics
Brain — hypertensive encephalopathy	Headache, confusion, visual changes, seizures, papilledema	CT/MRI head; fundoscopy
Brain — ischemic stroke	Focal neurologic deficits	CT head; CTA
Brain — hemorrhagic stroke/SAH	Thunderclap headache, neurologic deficits	CT head
Heart — acute HF/pulmonary edema	Dyspnea, rales, S3, JVD	CXR, BNP, echo
Heart — ACS	Chest pain, ECG changes, troponin elevation	ECG, troponins
Aorta — acute dissection	Tearing chest/back pain, BP differential between arms	CTA aorta
Kidney — acute renal injury	Oliguria, rising Cr, hematuria, proteinuria	BMP, UA with microscopy
Blood — TMA/MAHA	Schistocytes, thrombocytopenia, elevated LDH	CBC, smear, LDH, haptoglobin
Pregnancy — eclampsia/preeclampsia	Seizures, proteinuria, elevated LFTs, thrombocytopenia	Labs, urine protein, fetal monitoring

Hypertensive Urgency (no end-organ damage):

• Severely elevated BP (often > 180/120) but no acute target organ injury
• Manage with oral agents; aim for gradual reduction over 24–48 hours
• Common scenario: medication non-adherence with asymptomatic BP elevation

---

Step 2: BP Reduction Targets by Presentation

General Principle: Reduce MAP by no more than 25% in the first hour, then to 160/100 over the next 2–6 hours, then gradually to normal over 24–48 hours.

Presentation-Specific Targets:

Presentation	First-Hour Target	2–6 Hour Target	Agent of Choice
Hypertensive encephalopathy	Reduce MAP by 20–25%	160/100	Nicardipine or labetalol
Acute ischemic stroke (no tPA)	< 220/120 (permissive)	Maintain < 220/120	Labetalol or nicardipine
Acute ischemic stroke (tPA eligible)	< 185/110 pre-tPA; < 180/105 post-tPA	Maintain target	Labetalol or nicardipine
Hemorrhagic stroke	SBP < 140 (INTERACT2/ATACH-2)	Maintain < 140	Nicardipine or clevidipine
Aortic dissection	SBP < 120 AND HR < 60 within 20 min	Maintain target	Esmolol + nicardipine (BB first to prevent reflex tachycardia)
Acute pulmonary edema	Reduce MAP by 25%	Afterload reduction	Nitroglycerin or nitroprusside + furosemide
ACS	Reduce to relieve ischemia	Titrate to symptoms	Nitroglycerin, esmolol
Eclampsia/preeclampsia	SBP < 160, DBP < 110	Maintain target	IV labetalol or IV hydralazine; magnesium for seizure prophylaxis
Pheochromocytoma crisis	Reduce BP gradually	Titrate to symptoms	Phentolamine (alpha-blocker first; never BB alone)

---

Step 3: IV Antihypertensive Selection

First-Line IV Agents:

Agent	Mechanism	Dose	Onset	Notes
Nicardipine	DHP CCB	5–15 mg/hr IV infusion	5–15 min	Preferred in most emergencies; titratable
Labetalol	Combined α/β-blocker	20 mg IV bolus, then 0.5–2 mg/min infusion	5–10 min	Avoid in acute HF, asthma, cocaine
Esmolol	β1-selective	500 mcg/kg bolus → 50–200 mcg/kg/min	1–2 min	Ultra-short acting; ideal for dissection
Clevidipine	DHP CCB	1–2 mg/hr → titrate by doubling q90s (max 32 mg/hr)	2–3 min	Ultra-short acting; lipid-based emulsion
Nitroglycerin	Venodilator	5–200 mcg/min	2–5 min	Best for ACS, pulmonary edema
Nitroprusside	Arterial + venous dilator	0.25–10 mcg/kg/min	Immediate	Cyanide toxicity risk > 48 hours; avoid in renal failure
Fenoldopam	D1-agonist	0.1–1.6 mcg/kg/min	5–15 min	Renal protective; avoid with glaucoma
Hydralazine	Direct vasodilator	10–20 mg IV q4–6h	10–20 min	Unpredictable; use in eclampsia when labetalol unavailable
Phentolamine	Alpha-blocker	5–15 mg IV bolus	1–2 min	Pheochromocytoma/catecholamine excess only

---

Step 4: Monitoring and Titration Protocol

ICU Monitoring Requirements:

• Arterial line (A-line) for continuous BP monitoring is recommended for all hypertensive emergencies
• If A-line not available: automated cuff cycling every 5 minutes during acute titration, then every 15 minutes once stable
• Continuous telemetry for arrhythmia detection
• Hourly neurologic checks (GCS, pupil response, focal deficits)
• Strict I/O monitoring
• Repeat end-organ labs every 6–12 hours (Cr, troponin, LDH, smear as indicated)

Titration Rules:

• Nicardipine: start 5 mg/hr, increase by 2.5 mg/hr every 5–15 minutes to max 15 mg/hr
• Labetalol: 20 mg IV push over 2 min, repeat 40–80 mg every 10 min (max 300 mg total), or start infusion
• Esmolol: adjust infusion by 25–50 mcg/kg/min every 5–10 minutes
• Once BP at target for 6–8 hours on IV: begin oral overlap and wean IV

---

Step 5: Transition to Oral Therapy

Oral Agent Selection (overlap with IV for 4–6 hours before discontinuing IV):

Agent	Dose	Notes
Amlodipine	5–10 mg daily	Long-acting CCB; good for nicardipine bridge
Lisinopril/Enalapril	5–20 mg daily	ACEi; avoid in AKI, bilateral RAS, pregnancy
Losartan/Valsartan	25–160 mg daily	ARB alternative to ACEi
Labetalol PO	100–400 mg BID	Bridge from IV labetalol
Metoprolol	25–200 mg daily	Alternative beta-blocker
Clonidine	0.1–0.3 mg BID	Useful for medication non-adherence; risk of rebound

Discharge Planning:

• Confirm stable BP on oral regimen × 24 hours before discharge
• Address root cause of crisis (medication non-adherence, secondary hypertension, substance use)
• Screen for secondary hypertension if indicated (aldosterone/renin, renal duplex, catecholamines, sleep study)
• Close follow-up within 1 week post-discharge

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the classification (emergency vs. urgency) correct with end-organ damage documented?
2. Is the BP reduction target specific to the clinical presentation?
3. Is the IV agent selection appropriate for the organ system involved?
4. Is the monitoring protocol documented (A-line, telemetry, neuro checks)?
5. Is the oral transition plan with follow-up documented?

---

Quality Audit

• BP documented in both arms
• Emergency vs. urgency correctly classified
• End-organ damage systematically assessed across all systems
• Presentation-specific BP target documented
• Rate of BP reduction appropriate (not too fast)
• IV agent selected based on clinical scenario
• Drug dose, titration parameters, and max dose documented
• Continuous monitoring modality specified (A-line preferred)
• Serial labs ordered to track end-organ recovery
• Aortic dissection evaluated with BB before vasodilator
• Oral transition plan with medication, dose, and overlap period
• Root cause of crisis identified and addressed
• Follow-up appointment within 1 week documented
• Medication reconciliation and adherence counseling documented

---

Guidelines

1. Always distinguish hypertensive emergency from urgency before selecting treatment — urgencies do not need IV therapy and overly aggressive reduction causes harm.
2. In aortic dissection, start beta-blocker BEFORE any vasodilator to prevent reflex tachycardia and increased aortic shear stress — esmolol is preferred.
3. For acute ischemic stroke without thrombolytic candidacy, permissive hypertension (< 220/120) is appropriate — aggressive BP lowering worsens outcomes by reducing perfusion to penumbra.
4. Nitroprusside should be avoided in renal failure and limited to < 48 hours due to cyanide/thiocyanate toxicity risk — use nicardipine or clevidipine instead.
5. Hydralazine is unpredictable in onset and duration — avoid as first-line except in eclampsia when labetalol is unavailable.
6. In pheochromocytoma crisis, NEVER give a beta-blocker before adequate alpha-blockade — unopposed alpha stimulation causes paradoxical BP elevation.
7. Cocaine-associated hypertensive emergency should be treated with benzodiazepines, nicardipine, or phentolamine — avoid beta-blockers (risk of unopposed alpha stimulation).
8. Document the specific reason the BP crisis occurred — medication non-adherence is the most common cause and requires structured counseling, simplified regimens, and close follow-up.